EUVIMEDEUVIMED entdecken
Crossref

Is Bevacizumab a Risk Factor for Colon Stent-Related Perforation?

J. Lee, S. J. Kim, J. H. Lee

Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S339-S340

DOI: 10.1055/s-0044-1783526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von J. Lee und 2 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Self-expandable metal stent (SEMS) insertion is an effective treatment for acute malignant colonic obstruction and stenosis. Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factors and has been reported as a risk factor for stent-related perforation. However, the evidence for the association between bevacizumab and stent-related perforation is lacking.

Methods

From March 1, 2014 to December 31, 2018, we retrospectively analyzed patients with SEMS implantation due to acute colorectal obstruction of advanced colorectal cancer at four tertiary hospitals.

Results

A total 397 patients underwent SEMS placement in this period. Technical success and clinical success were achieved in 391 patients (98.2%), 392 patients (98.5%). Perforation occurred in 17 cases (4.2%). There was no difference in the incidence of perforation with or without bevacizumab treatment (9/138 vs 8/259 patients, p=0.108). Of the 17 patients who developed perforation, six patients had peri-procedural perforation and eleven patients had delayed perforation Conclusions Insertion of SEMS into colonic obstruction or stricture is a very safe procedure. Our findings suggest that bevacizumab does not increase the risk of stent-related perforation. [ 1 ] [ 2 ] [ 3 ] [ 4 ] [ 5 ] Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Lee, J., Kim, S. J., & Lee, J. H. (2024). Is Bevacizumab a Risk Factor for Colon Stent-Related Perforation?. Endoscopy, 56(S 02 S 02), S339-S340. https://doi.org/10.1055/s-0044-1783526

Vancouver

Lee J, Kim SJ, Lee JH. Is Bevacizumab a Risk Factor for Colon Stent-Related Perforation?. Endoscopy. 2024;56(S 02 S 02):S339-S340. doi:10.1055/s-0044-1783526

BibTeX
@article{Lee2024,
  author = {Lee, J. and Kim, S. J. and Lee, J. H.},
  title = {Is Bevacizumab a Risk Factor for Colon Stent-Related Perforation?},
  journal = {Endoscopy},
  year = {2024},
  volume = {56},
  number = {S 02 S 02},
  pages = {S339--S340},
  doi = {10.1055/s-0044-1783526}
}
Kostenlos starten →